Results from an early safety study of Moderna's coronavirus vaccine candidate in older adults showed that it produced virus-neutralizing antibodies at levels similar to those seen in younger adults,..
The drug giant said it would begin a stage three trial of a single-shot vaccine, which could prove easier to administer than rivals that require two inoculations. This report produced by Zachary..